Safety of Adalimumab Biosimilar MSB11022 (Acetate-Buffered Formulation) in Patients With Moderately-To-Severely Active Rheumatoid Arthritis

Clinical Rheumatology - United Kingdom
doi 10.1007/s10067-019-04679-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

OP0021 Efficacy and Safety Results of a Phase Iii Study Comparing Fkb327, an Adalimumab Biosimilar, With the Adalimumab Reference Product in Patients With Active Rheumatoid Arthritis

2017English

AB0954 a Randomised, Double-Blind Trial Comparing the Efficacy, Safety and Immunogenicity of Msb11022, a Proposed Biosimilar of Adalimumab, Versus Adalimumab Originator in Patients With Moderate-To-Severe Plaque Psoriasis

2018English

Fri0087 Efficacy, Safety, and Immunogenicity Results of the Switch From Reference Adalimumab (Refadl) to Sandoz Biosimilar Adalimumab (Gp2017, SDZ-Adl) From Admyra Phase 3 Study in Patients With Moderate-To-Severe Rheumatoid Arthritis (Ra)

2019English

Adalimumab Discontinuation in Patients With Rheumatoid Arthritis After Achieving Sustained Remission

Nauchno-Prakticheskaya Revmatologiya
RheumatologyAllergyImmunology
2018English

Comparative Clinical Efficacy and Safety of the Proposed Biosimilar ABP 710 With Infliximab Reference Product in Patients With Rheumatoid Arthritis

Arthritis Research & Therapy
2020English

Rheumatoid Arthritis-Associated Uveitis Treated With Adalimumab

Klinika Oczna
MedicineOphthalmology
2019English

Long-Term Treatment of Rheumatoid Arthritis With Adalimumab

Open Access Rheumatology: Research and Reviews
Rheumatology
2013English

Adalimumab With or Without Methotrexate in Juvenile Rheumatoid Arthritis

New England Journal of Medicine
Medicine
2008English

Lethality of Patients With Rheumatoid Arthritis Depending on Adalimumab Administration: Imitation Modeling

Nauchno-Prakticheskaya Revmatologiya
RheumatologyAllergyImmunology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy